Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

NS-2710 in development for anxiety

Sep. 6, 1996

Melatonergic agents from ADIR

Sep. 6, 1996

BTG licenses analgesic combination to Forest

Sep. 6, 1996

FDA approves two pain products from Mallinckrodt

Sep. 6, 1996

NPC-18521, a high-affinity bradykinin B2 receptor antagonist from Scios

Sep. 6, 1996

New introductions for Faulding's sustained-release morphine product

Sep. 6, 1996

Analgesic and antiinflammatory agents superior to capsaicin

Sep. 6, 1996

Lilly's new AMPA antagonist, LY-311446

Aug. 30, 1996

AChE inhibitor isolated from Penicillium at Kitasato Institute

Aug. 30, 1996

PLA2 role in Alzheimer's disease suggested

Aug. 30, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...